Articles related to KIDNEY DISEASE

A recent study involving 20,440 older adults with kidney failure found that initiating dialysis at an eGFR below 12 mL/min/1.73 m2 resulted in a mean survival of 770 days over a 3-year period, compared to 761 days for those continuing medical management

Extraosseous calcification in chronic and end-stage kidney disease involves a complex pathogenesis, impacting patient morbidity and mortality through vascular, soft tissue, and calciphylaxis manifestations.

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

Acquired reactive perforating collagenosis, characterized by pruritic eruptions and systemic associations, often manifests in patients with diabetes or chronic kidney disease, underscoring the necessity for holistic patient assessment in dermatological evaluations.

In patients with chronic kidney disease, the elevated troponin challenge necessitates a nuanced approach, integrating serial measurements and clinical context to discern acute coronary syndrome from chronic elevations, thereby informing targeted management strategies.